A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-11 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
The men's basketball team has been one of the nation's most successful programs since Lute Olson was hired as head coach in 1983, and is still known as a national powerhouse in Division I men's basketball. Between 1985 and 2009, the team reached the NCAA Tournament 25 consecutive years, which is the third-longest streak in NCAA history, after Kansas, with appearances from 1990–present, North Carolina, with 27 consecutive appearances from 1975 to 2001. The Wildcats have reached the Final Four of the NCAA tournament in 1988, 1994, 1997, 2001, and 2026. In 1997, Arizona defeated the University of Kentucky, the then-defending national champions, to win the NCAA National Championship (NCAA Men's Division I Basketball Championship) by a score of 84–79 overtime; Arizona's first national championship victory. The 1997 championship team became the first and only in NCAA history to defeat three number-one seeds en route to a national title (Kansas, North Carolina, and Kentucky—the North Carolina game being the final game for longtime UNC head coach Dean Smith). Point guard Miles Simon was chosen as 1997 Final Four MVP (Simon was also an assistant coach under Olson from 2005 to 2008). The Cats also boast the third-highest winning percentage in the nation over the last twenty years. Arizona has won a total of 28 regular season conference championships in its program's history, and 6 PAC-12 tournaments. Since 2005, Arizona has produced 17 NBA draft picks. The Wildcats play their home games at the McKale Center in Tucson.
Bakery (packaged and sometimes a service bakery and/or onsite bakery) Beverages (non-alcoholic packaged, sometimes also alcoholic if laws permit) Nonfood & Pharmacy (e.g. cigarettes, lottery tickets and over-the-counter medications (as laws permit), DVD rentals, books and magazines, including supermarket tabloids, greeting cards, toys, small selection of home goods like light bulbs, housewares (typically limited) Personal care e.g. cosmetics, soap, shampoo Produce (fresh fruits and vegetables) Floral (flowers and plants) Deli (sliced meats, cheeses, etc.) Prepared Foods (packaged and frozen foods) Meat (fresh packaged, frozen, sometimes with a butcher service counter) Seafood (fresh packaged, frozen, sometimes with a butcher service counter) Dairy (milk products and eggs) Center store (e.g. detergent, paper products, household cleaning supplies) Multicultural (ethnic foods) Bulk dried foods Animal foods, toys and products
=== Chemical treatments === Preservation librarians use a number of different chemicals to prevent the growth of mold spores. Chemical compounds such as ethylene oxide, thymol, and orthophenyl phenol are regularly used. Chlorine dioxide is a chemical that started growing in popularity in the early 2000's due its safety level for library employees and patrons. These chemicals act as effective sporicides in a variety of library settings. They are applied on books and surrounding shelves by manual wiping or using chlorine packets that release the chemicals in gaseous form into the air. Chemical treatments are often used in enclosed storage areas with little air circulation. They are also used to deal with emergency situations involving mold outbreaks caused by pipe leaks in buildings. In 2000, the University of Oklahoma Libraries conducted an evaluation of the effects of chlorine packets on mold growth. Paper items that had been exposed to the substance showed lower overall pH levels than items that had not been treated. Although long-term effects of chemical treatments on paper permanence and other library materials have not been documented, libraries use this newer method of controlling mold in the stacks.
Each medal has a portrait of Alfred Nobel in left profile on the obverse. The medals for Chemistry, Literature, Physics, and Physiology or Medicine have identical obverses, showing the image of Nobel and the years of his birth and death. Nobel's portrait also appears on the obverse of the Peace Prize medal and the Economics Prize medal, but with a slightly different portrait. The names of the chemistry, medicine, literature and physics prize recipients are engraved on the reverse of the medal on a small plate. The names of the peace and economic prize recipients are engraved on the edges of their medals. The Chemistry, Literature, Physics, and Physiology or Medicine medals were designed by Erik Lindberg. The Peace prize medal was designed by Gustav Vigeland, and the Economics prize medal by Gunvor Svensson-Lundqvist. The inaugural Nobel laureates of 1901 received a 'temporary' medal that was struck in a lesser metal than gold. The first medals were eventually struck in September 1902. The delay was due to the designs needing to be approved by each respective awarding institution. The medals were designed by the sculptor Erik Lindberg. Between 1902 and 2010 the Nobel Prize medals were struck by the Myntverket, the Swedish royal mint, located in Eskilstuna. In 2011 the medals were made by Det Norske Myntverket in Kongsberg. The medals have been made by Svenska Medalj in Eskilstuna since 2012 with the exception of the peace prize medal which is made by the Det Norske Myntverket.
Sources: en.wikipedia.org
==== The Yellow Emperor's Classic of Internal Medicine (475 BC – 8 AD) ==== Huángdì Nèijīng (黃帝內經), or The Yellow Emperor's Classic of Internal Medicine, is a fundamental ancient text in Chinese medicine and a major book of Daoist philosophy and lifestyle. It is generally dated to the late Warring States period (475–221 BC) and the Western Han dynasty (206 BC – 8 AD). The text named the condition xiāo kě (消渴; "wasting-thirst") and elaborated on it through 25 clauses. It recorded such symptoms as "three increases [excess] and one decrease [loss]": excessive thirst (polydypsia), excessive hunger (polyphagia), excessive urine (polyuria), and weight loss. Three sub-phases of xiāo kě were given, characterized by their dominant symptoms. These roughly correspond to the progressive stages of diabetes in modern-day Western medicine.
== Medical use == Both T3 and T4 are used to treat thyroid hormone deficiency (hypothyroidism). They are both absorbed well by the stomach, so they can be given orally. Levothyroxine is the chemical name of the manufactured version of T4, which is metabolised more slowly than T3 and hence usually needs only once-daily administration. Natural desiccated thyroid hormones are derived from pig thyroid glands, and are a "natural" hypothyroid treatment containing 20% T3 and traces of T2, T1 and calcitonin. Also available are synthetic combinations of T3/T4 in different ratios (such as liotrix) and pure-T3 medications (INN: liothyronine). Levothyroxine sodium is usually the first course of treatment tried. Some patients report better outcomes with desiccated thyroid hormone; however, this is based on anecdotal evidence, and clinical trials have not shown any benefit over biosynthetic forms. Thyroid tablets are reported to have different effects, which can be attributed to the difference in torsional angles surrounding the reactive site of the molecule. Thyronamines have no medical usages yet, though their use has been proposed for controlled induction of hypothermia, which causes the brain to enter a protective cycle and can be useful in preventing damage during ischemic shock. Synthetic thyroxine was first successfully produced by Charles Robert Harington and George Barger in 1926.
, where i(θ) is the scattering function of a single particle, k = 2πn0/λ0, n0 is the refractive index of the suspending fluid, and λ0 is the vacuum wavelength of the incident light. The excess Rayleigh ratio, R(θ), is then given by
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.